Phase I and II clinical trials of multiple immunotherapies, including nivolumab and ipilimumab, to treat patients with acute myeloid leukaemia, chronic lymphocytic leukaemia, chronic myeloid leukaemia, myelodysplastic syndromes and myelofibrosis.

Trial Profile

Phase I and II clinical trials of multiple immunotherapies, including nivolumab and ipilimumab, to treat patients with acute myeloid leukaemia, chronic lymphocytic leukaemia, chronic myeloid leukaemia, myelodysplastic syndromes and myelofibrosis.

Planning
Phase of Trial: Phase II

Latest Information Update: 13 Oct 2014

At a glance

  • Drugs Immunotherapies (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary)
  • Indications Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Chronic myeloid leukaemia; Myelodysplastic syndromes; Myelofibrosis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 13 Oct 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top